Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sapp

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
FEMS Immunology and Medical Microbiology|December 4, 2008
Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patientsTania V Lopez, Clotilde Cancio, Fernando Cruz-Talonia, et al.
Journal of Medical Virology|November 16, 2004
Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISAOliver Rommel, Joakim Dillner, Claudia Fligge, et al.
Journal of Virology|April 26, 2013
Human papillomavirus types 16, 18, and 31 share similar endocytic requirements for entryGilles Spoden, Lena Kühling, Nicole Cordes, et al.
Journal of Virology|August 10, 2007
Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirusHans-Christoph Selinka, Luise Florin, Hetal D Patel, et al.
Journal of Virology|May 14, 2004
Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70Luise Florin, Katrin A Becker, Cornelia Sapp, et al.
The Journal of General Virology|December 2, 1999
Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesisIlvars Silins, Zhaohui Wang, Elisabeth Åvall-Lundqvist, et al.
Journal of Virology|June 16, 2006
Identification of a dynein interacting domain in the papillomavirus minor capsid protein l2Luise Florin, Katrin A Becker, Carsten Lambert, et al.
Journal of Virology|August 7, 2015
Topography of the Human Papillomavirus Minor Capsid Protein L2 during Vesicular Trafficking of Infectious EntryStephen DiGiuseppe, Timothy R Keiffer, Malgorzata Bienkowska-Haba, et al.
Cellular Microbiology|November 19, 2016
Incoming human papillomavirus 16 genome is lost in PML protein-deficient HaCaT keratinocytesMalgorzata Bienkowska-Haba, Wioleta Luszczek, Timothy R Keiffer, et al.
The Journal of Biological Chemistry|July 21, 2007
Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfateMaren Knappe, Sabrina Bodevin, Hans-Christoph Selinka, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
FEMS Immunology and Medical Microbiology|December 4, 2008
Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patientsTania V Lopez, Clotilde Cancio, Fernando Cruz-Talonia, et al.
Journal of Medical Virology|November 16, 2004
Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISAOliver Rommel, Joakim Dillner, Claudia Fligge, et al.
Journal of Virology|April 26, 2013
Human papillomavirus types 16, 18, and 31 share similar endocytic requirements for entryGilles Spoden, Lena Kühling, Nicole Cordes, et al.
Journal of Virology|August 10, 2007
Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirusHans-Christoph Selinka, Luise Florin, Hetal D Patel, et al.
Journal of Virology|May 14, 2004
Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70Luise Florin, Katrin A Becker, Cornelia Sapp, et al.
The Journal of General Virology|December 2, 1999
Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesisIlvars Silins, Zhaohui Wang, Elisabeth Åvall-Lundqvist, et al.
Journal of Virology|June 16, 2006
Identification of a dynein interacting domain in the papillomavirus minor capsid protein l2Luise Florin, Katrin A Becker, Carsten Lambert, et al.
Journal of Virology|August 7, 2015
Topography of the Human Papillomavirus Minor Capsid Protein L2 during Vesicular Trafficking of Infectious EntryStephen DiGiuseppe, Timothy R Keiffer, Malgorzata Bienkowska-Haba, et al.
Cellular Microbiology|November 19, 2016
Incoming human papillomavirus 16 genome is lost in PML protein-deficient HaCaT keratinocytesMalgorzata Bienkowska-Haba, Wioleta Luszczek, Timothy R Keiffer, et al.
The Journal of Biological Chemistry|July 21, 2007
Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfateMaren Knappe, Sabrina Bodevin, Hans-Christoph Selinka, et al.
Pageof 5